MediWhale has been selected as the lead agency for the Ministry of Trade, Industry and Energy's new biohealth research and development project.

MediWhale , a medical artificial intelligence (AI) company, announced on the 29th that it has been selected as the implementing agency for a new project in the bioindustry technology development field of the "2025 Second Biohealth Research and Development Project," hosted by the Ministry of Trade, Industry and Energy. Through this project, MediWhale will begin full-scale research with the goal of developing and commercializing an early diagnosis AI platform that combines hardware and software.

The Biohealth Research and Development Project is a strategic support program of the Ministry of Trade, Industry and Energy aimed at fostering future growth industries and strengthening the competitiveness of the nation's advanced industries by securing core and original technologies in the biohealth field.

This project, led by MediWhale, is titled "Commercialization of a Deep Learning-Based Integrated Digital Healthcare Platform for Personalized Management of Dry Macular Degeneration." Its core focus is the development of digital health technologies for early diagnosis and prognosis management of macular degeneration. The project will receive a total of KRW 5.7 billion in government funding and is scheduled to run for five years, ending in 2029.

As the lead organization, MediWhale oversees the overall platform design and integrated hardware and software development, and promotes technology development through collaboration with collaborating research institutions. The joint research includes the Korea Electrotechnology Research Institute, Kangwon National University Industry-Academic Cooperation Foundation, Dankook University Cheonan Campus Industry-Academic Cooperation Foundation, and Yonsei University Industry-Academic Cooperation Foundation. Each institution is responsible for specific technologies, including precision optical technology, image preprocessing, photobiomodulation-based treatment technology, and clinical data provision and verification.

MediWhale CEO Choi Tae-geun said, “Through this project, we have expanded MediWhale’s AI-based retinal diagnostic technology into the hardware domain,” and “Through collaboration with joint research institutions, we will build an integrated diagnostic platform that can be applied in actual medical settings.”

• See more related articles